Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shensong Yangxin Capsule after radiofrequency ablation for persistent atrial fibrillation
ChiCTR1900026912Phase 4Recruiting
- Sponsor
- People's Hospital of Wuhan University
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of shensong yangxin capsule in Atrial fibrillation (AFib) (2 arms), sponsored by People's Hospital of Wuhan University. Primary endpoint: atrial fibrillation recurrence. Started Apr 2019; status: recruiting.
02
Drugs
shensong yangxin capsule
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR1900026912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026912.